Implementation of an Allergic Rhinitis Severity Questionnaire in ENT Consultations

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07315945

Acronym

QSRA-ORL

Enrollment

Registered

2026-01-05

Start date

2025-06-10

Completion date

2026-02-28

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

Allergic Rhinitis, SCST score, SNOT 22 score

Brief summary

Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses). Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression. Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult (≥18 years) * Follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis

Exclusion criteria

* Asymptomatic individuals not requiring follow-up consultations.

Design outcomes

Primary

Measure	Time frame	Description
Self-Assessment Clinical Symptom Score (SCST)	Up to 6 months	1. Rating Scale Each symptom is rated by the patient according to its intensity: * 0: absent * 1: mild * 2: moderate * 3: severe 2. Calculating the Score * Add the scores for each symptom. * The total SCST score reflects the overall severity of the symptoms: * Low score → mild symptoms * High score → severe symptoms 3. Interpretation * Before treatment: establish a baseline. * After treatment: compare the scores to assess effectiveness. * A decrease in the score indicates clinical improvement.

Countries

France

Contacts

Primary ContactLéa FATH, MD

lea.fath@chru-strasbourg.fr33 3 88 12 76 52

Outcome results